Cargando…
Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies
Cluster of differentiation 40 (CD40) mediates many immune activities. Preclinical studies have shown that activation of CD40 can evoke massive antineoplastic effects in several tumour models in vivo, providing a rationale for using CD40 agonists in cancer immunotherapy. To date, several potential ag...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471753/ https://www.ncbi.nlm.nih.gov/pubmed/32934743 http://dx.doi.org/10.3892/ol.2020.12037 |